Dr Chris Kramer on the Clinical Importance of Finerenone for Patients With Heart Failure
Finerenone, a mineralocorticoid receptor antagonist, showed reduced heart failure exacerbations and cardiovascular deaths in patients with ejection fractions >40%, per the FINEARTS study presented at the 2024 ESC Congress.
Highlighted Terms
Related News
Finerenone reduced heart failure events and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to a Brigham and Women's Hospital-led trial. Hyperkalemia rates were higher in the finerenone group. Results published in the New England Journal of Medicine.
Finerenone, a mineralocorticoid receptor antagonist, showed reduced heart failure exacerbations and cardiovascular deaths in patients with ejection fractions >40%, per the FINEARTS study presented at the 2024 ESC Congress.
Finerenone reduced heart failure events and cardiovascular death in HF patients with mildly reduced or preserved ejection fraction, according to a Brigham and Women's Hospital-led trial. The drug showed benefits regardless of ejection fraction and in patients on other therapies, suggesting it could be a new therapeutic option for HF, affecting over 60 million worldwide.
Finerenone reduced HF events and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to a trial led by Brigham and Women’s Hospital. The drug showed benefits regardless of ejection fraction and even with other therapies, suggesting it could be a new therapeutic option for HF patients. The trial, funded by Bayer, had limitations including few Black participants. Results were presented at the European Society of Cardiology Congress 2024 and published in the New England Journal of Medicine.
Finerenone reduced CV death and worsening HF risk by 16% in HF patients with mildly reduced or preserved ejection fraction, per FINEARTS-HF trial. Pooled analyses showed benefits of finerenone and MRAs in high-risk patients.
Finerenone reduced heart failure events and cardiovascular death in HF patients with mildly reduced or preserved ejection fraction. The trial, led by Brigham and Women's Hospital and funded by Bayer, showed fewer HF events and cardiovascular deaths in the finerenone group compared to placebo, with higher rates of hyperkalemia. Results were presented at the European Society of Cardiology Congress 2024 and published in the New England Journal of Medicine.
The Phase III FINEARTS-HF trial presented at the ESC conference showed Bayer's Kerendia (finerenone) significantly reduced CV death and HF events by 16% in HF patients with LVEF ≥40%. Finerenone, a non-steroidal MRA, demonstrated safety and efficacy in a double-blind, placebo-controlled study, with findings consistent across subgroups. Kerendia, initially approved for chronic kidney disease with type 2 diabetes, may expand its use to HF pending FDA approval.